DRI Healthcare Trust is an unincorporated open-ended company. The company is headquartered in Toronto, Ontario and currently employs 32 full-time employees. The company went IPO on 2021-02-11. The firm provides capital to universities and research institutions, academic institutions, biotechnology companies and pharmaceutical companies. The company has acquired more than 75 royalties on 45-plus drugs, including Ekterly, Eylea, Keytruda, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga. Its portfolio includes Empaveli/Syfovre, Eylea I, Eylea II, Natpara, Omidria, Oracea, Orserdu I, Orserdu II, Rydapt, Vonjo I, Vonjo II, Xenpozyme, Xolair, Zejula, and other products. Its therapeutic areas include oncology, neurology, ophthalmology, endocrinology, hematology, dermatology, lysosomal storage disorders (LSD) and immunology. The Company’s products are marketed by pharmaceutical companies, including Regeneron, Bayer, Santen; Vertex Pharmaceuticals; KalVista, Galderma and others.
Dri Healthcare Trust lĩnh vực doanh thu lớn nhất là Natural Gas, với doanh thu 164,899,611,314 trong báo cáo lợi nhuận gần đây. Về mặt địa lý, China, Kazakhstan, Oman, Thailand là thị trường chính cho Dri Healthcare Trust, với doanh thu 202,799,741,586.
Dri Healthcare Trust 是否盈利?
không có,根據最新的財務報表,Dri Healthcare Trust 的淨thua lỗ為 $-50